
08/18/2025
🚀 PROTAC Therapies: From Concept to Late-Stage Clinical Reality
Proteolysis-targeting chimeras (PROTACs) are transforming the drug development landscape. While no PROTAC-based therapies have yet reached the market, the field is rapidly advancing:
🔬 40+ PROTAC drug candidates are now in clinical trials.
🎯 Targets include AR, ER, BTK, and IRAK4.
🩺 Applications span hematological cancers, solid tumors, and autoimmune disorders.
Notably, three PROTACs have advanced to Phase 3 trials:
√ ARV-471 (Vepdegestrant) – Arvinas/Pfizer (ER degrader) → NDA accepted by FDA, PDUFA: June 5, 2026
√ BMS-986365 – Bristol Myers Squibb (AR degrader)
√ BGB-16673 – BeiGene (BTK degrader)
🌟 With multiple late-stage programs and broad therapeutic potential, PROTACs are on the brink of becoming a new drug class in modern medicine.
👉 Do you think the first FDA-approved PROTAC will arrive by 2026?
https://www.biochempeg.com/article/434.html